GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Profitability Rank

Forty Seven (Forty Seven) Profitability Rank : 0 (As of Dec. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Profitability Rank?

Forty Seven has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Forty Seven's Operating Margin % for the quarter that ended in Dec. 2019 was %. As of today, Forty Seven's Piotroski F-Score is 0.


Competitive Comparison of Forty Seven's Profitability Rank

For the Biotechnology subindustry, Forty Seven's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forty Seven's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Forty Seven's Profitability Rank falls into.



Forty Seven Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Forty Seven has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Forty Seven's Operating Margin % for the quarter that ended in Dec. 2019 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2019 ) / Revenue (Q: Dec. 2019 )
=-24.563 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Forty Seven has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Forty Seven Profitability Rank Related Terms

Thank you for viewing the detailed overview of Forty Seven's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Forty Seven (Forty Seven) Business Description

Traded in Other Exchanges
N/A
Address
1490 O’Brien Drive, Suite A, Menlo Park, CA, USA, 94025
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Executives
Dennis Henner director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball director C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads officer: Chief Financial Officer 4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154

Forty Seven (Forty Seven) Headlines

From GuruFocus